Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute <font color="blue">invasive_1</font> <font color="blue">diarrhea_1</font> in children . 
<br>
<br> BACKGROUND Acute invasive diarrhea is a potentially serious condition in children . Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics , intramuscular ceftriaxone has become the routine drug in the treatment of acute invasive diarrhea requiring an emergency visit in southern Israel . The inconvenience of this parenteral regimen created an increased <font color="blue">need_1</font> <font color="blue">for_1</font> <font color="blue">oral_1</font> <font color="blue">pediatric_1</font> <font color="blue">formulations_1</font> for the treatment of invasive diarrhea . 
<br> OBJECTIVES To evaluate the <font color="blue">efficacy_4</font> <font color="blue">and_4</font> <font color="blue">safety_4</font> of a suspension formulation of ciprofloxacin in the treatment of acute <font color="blue">invasive_1</font> <font color="blue">diarrhea_1</font> in infants and children . 
<br> PATIENTS AND METHODS From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35% < 1 year ; 70% <3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were randomized to receive either ciprofloxacin suspension ( 10 mg / kg twice a day + i m placebo ; n = 95 ) or i m ceftriaxone ( 50 mg / kg / day + placebo suspension ; n = 106 ) for 3 days in a double blind manner . <font color="blue">Stool_3</font> <font color="blue">cultures_3</font> <font color="blue">for_2</font> <font color="blue">Shigella_3</font> <font color="blue">,_3</font> <font color="blue">Salmonella_3</font> <font color="blue">,_3</font> <font color="blue">Campylobacter_3</font> <font color="blue">spp_3</font> <font color="blue">._3</font> <font color="blue">and_3</font> <font color="blue">diarrheagenic_3</font> <font color="blue">Escherichia_3</font> <font color="blue">coli_3</font> were obtained on Days 1 , 3 , 4 to 5 and 21 + /- 5 . <font color="blue">Clinical_3</font> <font color="blue">response_3</font> <font color="blue">and_3</font> <font color="blue">safety_3</font> were assessed on Days 1 , 2 , 3 , 4 to 5 and 21 + /- 5 . 
<br> RESULTS We isolated 127 <font color="blue">pathogens_2</font> from 121 ( 60% ) patients : 73 ( 57% ) <font color="blue">Shigella_3</font> <font color="blue">;_3</font> <font color="blue">23_1</font> <font color="blue">(_1</font> <font color="blue">18%_1</font> <font color="blue">)_1</font> <font color="blue">Salmonella_3</font> <font color="blue">;_3</font> <font color="blue">18_1</font> <font color="blue">(_1</font> <font color="blue">14%_1</font> <font color="blue">)_1</font> <font color="blue">E._3</font> <font color="blue">coli_3</font> <font color="blue">;_3</font> <font color="blue">and_1</font> <font color="blue">13_1</font> <font color="blue">(_1</font> <font color="blue">10%_1</font> <font color="blue">)_1</font> <font color="blue">Campylobacter_3</font> <font color="blue">._2</font> <font color="blue">Overall_3</font> <font color="blue">bacteriologic_5</font> <font color="blue">eradication_5</font> <font color="blue">on_1</font> <font color="blue">Day_1</font> <font color="blue">4_1</font> <font color="blue">to_1</font> <font color="blue">5_1</font> was 99% for <font color="blue">Shigella_2</font> <font color="blue">,_2</font> <font color="blue">77%_1</font> <font color="blue">for_1</font> <font color="blue">Salmonella_2</font> <font color="blue">and_1</font> <font color="blue">77%_1</font> <font color="blue">for_1</font> <font color="blue">Campylobacter_2</font> <font color="blue">,_2</font> with no difference between the 2 groups . <font color="blue">Clinical_5</font> <font color="blue">cure_5</font> <font color="blue">or_5</font> <font color="blue">improvement_5</font> was observed in 100 and 99% of the ciprofloxacin and ceftriaxone groups , respectively . <font color="blue">Serum_5</font> <font color="blue">ciprofloxacin_5</font> <font color="blue">values_4</font> <font color="blue">determined_1</font> <font color="blue">on_1</font> <font color="blue">Day_1</font> <font color="blue">3_1</font> of the treatment were higher in the majority of patients than were the <font color="blue">MIC50_2</font> <font color="blue">and_2</font> <font color="blue">MIC90_2</font> <font color="blue">values_2</font> <font color="blue">for_2</font> <font color="blue">the_2</font> <font color="blue">Shigella_2</font> <font color="blue">and_2</font> <font color="blue">Salmonella_2</font> <font color="blue">spp_2</font> <font color="blue">._2</font> <font color="blue">isolated_2</font> <font color="blue">._2</font> <font color="blue">Possible_3</font> <font color="blue">drug_5</font> <font color="blue">-_5</font> <font color="blue">related_5</font> <font color="blue">adverse_5</font> <font color="blue">events_5</font> occurred in 13 patients [ ciprofloxacin , 8 ( 8% ) ; ceftriaxone , 5 ( 4.7% ) ] and were mild and transient . <font color="blue">Joint_2</font> <font color="blue">examination_2</font> was normal during and after completion of therapy in all patients . 
<br> CONCLUSION Oral ciprofloxacin was as <font color="blue">safe_2</font> <font color="blue">and_1</font> <font color="blue">effective_2</font> as intramuscular ceftriaxone for the empiric treatment of acute <font color="blue">invasive_1</font> <font color="blue">diarrhea_1</font> in ambulatory pediatric patients requiring an emergency room visit .